Answers are grounded in this paper and cite their sources.
Chimeric antigen receptor T cell (CAR-T) has advanced rapidly in hematologic malignancies and even solid tumors, but post-treatment adverse reactions remain a major risk. Most adverse reactions are associated with inflammatory responses and cytokine release, such as cytokine release syndrome. Cytokine adsorption is an extracorporeal blood-purification approach designed to adsorb circulating inflammatory mediators. We report three patients with CAR-T-associated CRS, CRS with ICANS, or CRS with IEC-HS who received CA330-based cytokine adsorption as part of multimodal management. Clinical recovery and reductions in selected inflammatory markers were observed during the treatment course, and no procedure-related adverse events were documented. However, because adsorption overlapped with anti-IL-6 therapy, corticosteroids, anti-infective and supportive care, and the natural evolution of these toxicities, its independent contribution could not be determined. These observations support the feasibility of this approach and warrant prospective evaluation.
No takes yet. Share an insight, caveat, or question.
Xu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: